Literature DB >> 27753435

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Douglas J Robertson1,2, Jeffrey K Lee3, C Richard Boland4, Jason A Dominitz5, Francis M Giardiello6, David A Johnson7, Tonya Kaltenbach8, David Lieberman9, Theodore R Levin10, Douglas K Rex11.   

Abstract

The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27753435     DOI： 10.1038/ajg.2016.492

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


  115 in total

1.  Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples.

Authors:  Lydia Guittet; Véronique Bouvier; Elodie Guillaume; Romuald Levillain; Angela Ruiz; Olivier Lantieri; Guy Launoy
Journal:  Dig Liver Dis       Date:  2012-04-22       Impact factor: 4.088

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer.

Authors:  H Nakama; B Zhang
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

Review 4.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

5.  Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations.

Authors:  Marion R Nadel; Zahava Berkowitz; Carrie N Klabunde; Robert A Smith; Steven S Coughlin; Mary C White
Journal:  J Gen Intern Med       Date:  2010-04-10       Impact factor: 5.128

6.  Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.

Authors:  Hermann Brenner; Sha Tao
Journal:  Eur J Cancer       Date:  2013-05-22       Impact factor: 9.162

7.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Authors:  James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

8.  Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.

Authors:  Deirdre McNamara; Ronan Leen; Chun Seng-Lee; Nikki Shearer; Paul Crotty; Paul Neary; Paul Walsh; Gerard Boran; Colm O'Morain
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 2.566

9.  Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems.

Authors:  Jessica Chubak; Michael P Garcia; Andrea N Burnett-Hartman; Yingye Zheng; Douglas A Corley; Ethan A Halm; Amit G Singal; Carrie N Klabunde; Chyke A Doubeni; Aruna Kamineni; Theodore R Levin; Joanne E Schottinger; Beverly B Green; Virginia P Quinn; Carolyn M Rutter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

10.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245
View more
  31 in total

1.  Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.

Authors:  Hermann Brenner; Silvia Calderazzo; Thomas Seufferlein; Leopold Ludwig; Nektarios Dikopoulos; Jörg Mangold; Wolfgang Böck; Thomas Stolz; Thomas Eisenbach; Thomas Block; Annette Kopp-Schneider; David Czock; Kaja Tikk
Journal:  JAMA       Date:  2019-05-07       Impact factor: 56.272

Review 2.  Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence.

Authors:  Kevin M Rank; Aasma Shaukat
Journal:  Curr Gastroenterol Rep       Date:  2017-08

3.  Optimizing the Quality of the Colorectal Cancer Screening Continuum: A Call to Action.

Authors:  Samir Gupta; Jesse Nodora
Journal:  J Natl Cancer Inst       Date:  2017-05-01       Impact factor: 13.506

4.  Importance of Age-Specific Insurer Perspective on Lifetime Cost Effectiveness of Colorectal Cancer Screening.

Authors:  Audrey H Calderwood
Journal:  Am J Gastroenterol       Date:  2018-10-29       Impact factor: 10.864

5.  Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples.

Authors:  Barbara Kinga Barták; Alexandra Kalmár; Bálint Péterfia; Árpád V Patai; Orsolya Galamb; Gábor Valcz; Sándor Spisák; Barnabás Wichmann; Zsófia Brigitta Nagy; Kinga Tóth; Zsolt Tulassay; Péter Igaz; Béla Molnár
Journal:  Epigenetics       Date:  2017-09-26       Impact factor: 4.528

6.  A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  Cancer       Date:  2017-07-28       Impact factor: 6.860

7.  Authors' Reply.

Authors:  Germaine Wong; Richard L Hope; Kirsten Howard; Jeremy R Chapman; Antoni Castells; Simon D Roger; Michael J Bourke; Petra Macaskill; Robin Turner; Gabrielle Williams; Wai H Lim; Charmaine E Lok; Fritz Diekman; Nicholas Cross; Shaundeep Sen; Richard D M Allen; Steven J Chadban; Carol A Pollock; Allison Tong; Armando Teixeira-Pinto; Jean Y H Yang; Narelle Williams; Eric Au; Anh Kieu; Laura James; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2019-10-09       Impact factor: 10.121

8.  Single dose aspirin affects fecal immunohistochemical test sensitivity in detecting advanced colorectal neoplasms: Truth or expectation?

Authors:  Yonca Yılmaz Ürün; Selim Aydemir
Journal:  Turk J Gastroenterol       Date:  2020-01       Impact factor: 1.852

9.  Colorectal Cancer Screening in the United States: What Is the Best FIT?

Authors:  David S Weinberg; Alan Barkun; Barbara J Turner
Journal:  Ann Intern Med       Date:  2016-10-25       Impact factor: 25.391

10.  Systematic review: Gut microbiota in fecal samples and detection of colorectal neoplasms.

Authors:  Efrat L Amitay; Agne Krilaviciute; Hermann Brenner
Journal:  Gut Microbes       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.